HER2+ Breast Cancer | Specialty

Novel Strategies for Treatment of Early Breast Cancer, Part I

October 25th 2012

Anthracyclines for Early-Stage HER2-Positive Breast Cancer

October 25th 2012

Hormonal and HER2-Targeted Therapy in Early Breast Cancer

October 25th 2012

Dr. Aithal on the HERceptin Adjuvant (HERA) Trial

October 25th 2012

Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.

Breast Oncologists Incorporate New Treatments, Grapple With Ongoing Challenges

October 5th 2012

During the 11th International Congress on The Future of Breast Cancer, Hope Rugo, MD, offered a snapshot of the research community's progress in the study and treatment of the disease.

One Year of Adjuvant Trastuzumab Remains Standard of Care

October 3rd 2012

Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.

Updated Data Show T-DM1 Improves Overall Survival in HER2-Positive Breast Cancer

October 1st 2012

An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Subcutaneous Trastuzumab May Offer Benefits Over Standard IV Infusion in Patients With Breast Cancer

September 26th 2012

A new formulation of trastuzumab that is administered subcutaneously appears to be as effective as the approved bodyweight-based intravenous regimen in women with HER2-positive breast cancer.

Beyond Tumor Type: HER2 Link in Leukemia Setting Shows Molecular Profiling Potential

September 21st 2012

Trastuzumab has demonstrated activity in patients with B-cell adult acute lymphocytic leukemia who exhibit evidence of upregulation of the HER2 receptor.

Dr. Hammond Discusses HER2 Testing Guideline Revisions

September 20th 2012

Pathologist Dr. Elizabeth Hammond, from Intermountain Healthcare, Discusses the Ongoing ASCO/CAP HER2 Testing Guideline Revisions.

Putting Key Developments in Two Tumor Types in Focus

July 27th 2012

As the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.

Dr. Baselga on Combining Pertuzumab with Trastuzumab

June 8th 2012

Dr. José Baselga, from Massachusetts General Hospital, on combining pertuzumab with trastuzumab

Identifying Appropriate Patients for HER2-Targeted Therapies

May 6th 2012

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.

Examining the HER2 Testing Puzzle: Fresh Research Explores Nagging Questions

March 27th 2012

HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.

Dr. Chang on Combining HER2 Targeted Therapies

March 22nd 2012

Dr. Jenny Chang, from the Methodist Cancer Center, Discusses Combining HER2 Targeted Therapies

Targeting HER2: Pertuzumab Puts the Spotlight on Dual Blockade Strategies

March 2nd 2012

Since the discovery of the HER2/neu gene in the late 1970s, aberrations in the HER2 signaling pathway have been implicated in a wide variety of human cancers.

2 Leading Breast Cancer Researchers Discuss Emerging Anti-HER2 Therapeutics

March 1st 2012

Dennis Slamon, MD, PhD, and Carlos L. Arteaga, MD, discuss recent advances in anti-HER2 targeted therapies and the role of signaling by oncogenes.

Dr. Bloom Explains Situations Requiring HER2 Retesting

February 16th 2012

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

Dr. Bloom Compares HER2 Screening Assays

January 30th 2012

Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays

HER2-Positive Patients Benefit From Combination Therapy of Trastuzumab and Lapatinib

January 17th 2012

Two new studies suggest that dual inhibition of HER2 might serve as a better approach to treating patients with HER2-positive breast cancer.